The European Medicines Agency (EMA) has accelerated the approval of Rasonque, a new drug for pancreatic cancer, using a phased review process that reduces the evaluation time to less than 150 days, thus allowing for a faster arrival of innovative treatments for patients without therapeutic alternatives. #CáncerDePáncreas #MedicamentosInnovadores #EMAEvaluación (translated)
www.abc.es
Europa acelera la llegada de medicamentos para enfermos sin tratamiento
